11/02/2019 10:30:00

Arrayit Corporation Nationwide Allergy Testing Network Doubles to More than 400 Healthcare Clinics

Sunnyvale, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its nationwide allergy testing consortium has more than doubled in the past six months to 410 medical clinics. The rapidly expanding network using the company’s powerful finger stick allergy testing services comprises 33 of the 48 continuous United States, with single clinics staffing as many as 70 doctors in the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions. Arrayit allergy testing services assist doctors in diagnosing and treating allergy and asthma, which impact up to 60 million Americans annually. Anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women's health are among the specialties included in Arrayit’s nationwide network. 

Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, fulfilled an FDA clinical instrumentation contract, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services, launched the Patient Data Solutions allergy portal for doctors and clinics, celebrated 25 years of company operations, announced an allergy testing services agreement with a major health and wellness provider, provided a letter to shareholders from the company’s Chief Executive Officer, aced four consecutive rounds of proficiency testing, and received endorsement by First Pediatrics Medical Group. Doubling the number of clinics in the nationwide network is expected to be an important driver of 2019 revenues and earnings. 

CEO Rene Schena states, “Our finger stick allergy testing services provide the speed, accuracy, sensitivity and ease of administration to advance personalized- and precision-based medicine approaches to the doctor-prescribed management of allergy and asthma. Doubling Arrayit’s nationwide network in six months is consistent with the significant value proposition afforded by our innovative, non-invasive technology and fully automated, physician-friendly system for allergy test ordering and reporting.” 

About Arrayit

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve human health and wellness. Please visit www.arrayit.com for more information.

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.

CONTACT

Public Relations

Arrayit Corporation

Tel: 408-744-1331

Email: arrayit@arrayit.com

Web: www.arrayit.com

CONTACT

Public Relations

Arrayit Corporation

Tel: 408-744-1331

Email: arrayit@arrayit.com

Web: www.arrayit.com

Arrayit-Corporation-Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
12 Feb
VELO
Hvis agendaen er at komme i en god position for en samlet overtagelse - er de vel godt på vej. I hve..
31
13 Feb
VELO
Her er nogle spørgsmål som jeg ønsker besvaret. Håber i andre vil bidrage med flere spørgsmål som JP..
24
12 Feb
PNDORA
Uden at skulle fremsætte nogen konspirationsteorier så finder jeg det personligt ganske interasant a..
23
12 Feb
GOMX
I får det seriøst til at lyde somom GomX er på vej ned og snakker dommedag 😂! Hallo bois!! Det førs..
20
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
11 Feb
VWS
MHI Vestas named as Preferred Supplier for 476 MW Baltic Eagle project in Germany http://www.mhivest..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
17
12 Feb
PNDORA
Fuldstændig uenig.Noget af Pandoras fald er absolut berettiget, ingen tvivl om det!   MEN.Pandora ha..
16
11 Feb
DSV
Der er nogen i denne her tråd, der burde skamme sig, og derefter lære at holde deres ubegavede ringe..
15
13 Feb
FING-B
Sådan skal de nye FPS kort fra Fingerprint Cards aktiveres. Smukt og ligetil https://m.youtube.com/..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Avon Products, Inc. (AVP) and Encourages AVP Investors to Contact the Firm
2
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Venator Materials PLC (VNTR) and Encourages VNTR Investors to Contact the Firm
3
Bragar Eagel & Squire, P.C. is Investigating Mattel, Inc. (MAT) on Behalf of Stockholders and Encourages MAT Investors to Contact the Firm
4
Bragar Eagel & Squire, P.C. Announces That Class Action Lawsuits Have Been Filed Against Molson Coors Brewing Company (TAP) and Encourages TAP Investors to Contact the Firm
5
200 First Responders to participate in Texas A&M Task Force 1 full-scale drill at Disaster City®

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 February 2019 16:27:42
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB3 - 2019-02-16 17:27:42 - 2019-02-16 16:27:42 - 1000 - Website: OKAY